The objective of this study is to describe the short-term change observed in CGM-related measures and relevant clinical variables in individuals with type 1 diabetes transitioning to Omnipod 5 insulin treatment within a real-world setting. The gene discussed is INS; the disease is type 1 diabetes mellitus.